Evidence map›Paper›PMID 39700219›Full record

ArticlePloS one2024

Advancing inclusive research calculator for oncology disease areas: A resource to support the development of enrollment targets in diversity action plans for industry sponsors.

David J Press, Spencer L James, Bruno Jolain, Nicole Richie

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

David J PressA Member of the Roche Group, Genentech, South San Francisco, California, United States of America.ORCID 0000-0003-3898-3156
Spencer L JamesA Member of the Roche Group, Genentech, South San Francisco, California, United States of America.
Bruno JolainF. Hoffman-La Roche Ltd., Basel, Switzerland.
Nicole RichieA Member of the Roche Group, Genentech, South San Francisco, California, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Food and Drug Omnibus Report Act, signed into law in 2022, requires industry sponsors to include diversity action plans in clinical study protocols. Defining reliable methodology for measures and benchmarks is critical to ensuring adequate and consistent representation of historically underrepresented patient populations in clinical trials.

methodsWe provide an Advancing Inclusive Research (AIR) Calculator, summary tables, and data query bank to support target setting for the development of diversity action plans and to take steps toward defining enrollment standards. The AIR Calculator uses data from the US Cancer Statistics database, which covers 100% of the US population. The database provides descriptive statistics for people diagnosed with 26 different cancers from 2015-2019 by cancer site, age at diagnosis, sex, and race and ethnicity, all stratified by stage at diagnosis (early, de novo metastatic, and combined). Descriptive characteristics include frequency counts, age-adjusted incidence rates, incidence rate ratios, and 95% CIs. Robustness test results are available in the data query bank by year of diagnosis.

resultsThis resource offers insights into distributions of cancer in the US. The AIR Calculator allows users to calculate representative clinical study distributions based on the sponsor-designated study size. DISCUSSION: The AIR Calculator serves as a valuable resource for planning of clinical studies, but additional data analyses are necessary for a comprehensive understanding at the study level. Comprehensive data collection and alignment across industry are essential to ensure consistent, accurate, and transparent benchmarks in historically underrepresented patient populations and to track progress toward the goal of improving their representation in clinical research.

Indexed as

NeoplasmsAdultAgedClinical Trials as TopicDatabases, FactualFemaleHumansMaleMedical OncologyMiddle AgedUnited States

Identifiers

PMID39700219
PMCPMC11658589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.